Case Study:

In 2021-2023, India undertook one of the largest vaccination drives in the world to combat viral infections. Scientists worked rapidly to develop vaccines using advanced biotechnology techniques such as recombinant DNA technology and viral vector platforms.

During clinical trials, a vaccine candidate showed 85% efficacy in preventing severe disease after two doses administered 28 days apart. The vaccine stimulated both humoral (antibody-mediated) and cell-mediated immune responses. After vaccination, memory B and T cells were formed, ensuring long-term protection.

In a district of Rajasthan, health workers observed that after vaccinating 70% of the population, infection rates dropped significantly. This indicated the development of herd immunity, where even unvaccinated individuals gained indirect protection.

However, challenges such as vaccine hesitancy, misinformation, and logistical issues in rural areas affected the program’s success. Some individuals experienced mild side effects like fever and fatigue, which were signs of immune activation.

This case highlights the principles of vaccine development, immune response, and public health strategies in India. It also emphasizes the importance of scientific innovation and community participation in disease control.

Questions:

Section A - MCQs

1. Vaccines provide long-term protection mainly due to:

A. Immediate destruction of pathogens
B. Formation of memory cells
C. Increase in body temperature
D. Reduction in blood pressure

2. Herd immunity is achieved when:

A. All individuals are infected
B. Majority of population is immune
C. Only children are vaccinated
D. No vaccines are used

3. Mild fever after vaccination indicates:

A. Failure of vaccine
B. Immune system activation
C. Infection by virus
D. DNA mutation

4. High vaccine efficacy (85%) means:

A. 85% people get infected
B. 85% reduction in disease risk among vaccinated
C. Vaccine works only once
D. 85% antibodies are destroyed

Section B - Short Answer Questions

1. Explain how vaccines stimulate both humoral and cell-mediated immunity.

2. Why is herd immunity important in controlling infectious diseases?

3. Analyze two major challenges faced during vaccination programs in India.

Section C - Long Answer Question

1. Suppose a new virus emerges and no vaccine is available.

• Explain the steps involved in developing a new vaccine.
• Discuss how biotechnology helps speed up vaccine production.
• Evaluate the importance of public participation in vaccination programs. 

Answer Key:

MCQs:

1. B
2. B
3. B
4. B

Short Answers:

1. Vaccines introduce antigens that activate B cells (producing antibodies) and T cells (killing infected cells), leading to both humoral and cell-mediated immunity.

2. Herd immunity reduces spread of infection by limiting transmission, protecting even those who are not vaccinated.

3.

• Vaccine hesitancy due to misinformation
• Logistical challenges in rural distribution

Long Answer:

Steps:

• Identification of antigen
• Preclinical testing
• Clinical trials (Phase I, II, III)
• Approval and mass production

Biotechnology Role:

• Recombinant DNA technology
• Rapid antigen production
• mRNA and viral vector platforms

Public Participation:
Essential for achieving herd immunity and ensuring success of vaccination programs.